Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company based in San Diego, California. The company is small, with 2 employees. Oncternal Therapeutics develops a range of treatments for cancers with significant unmet medical needs. Their pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development for hematologic cancers; TK-216, a small-molecule in Phase 1 development for Ewing sarcoma; and a CAR-T therapy targeting ROR1 in preclinical development for solid tumors and hematologic cancers. The company focuses drug development on promising biological pathways involved in cancer progression. Oncternal is dedicated to advancing its pipeline quickly and efficiently to provide patients with new, first-in-class cancer treatments. For more information, visit oncternal.com.